IMVT Ends Cutaneous Lupus Program After Phase 2 Miss

Immunovant is scrapping its lead antibody in cutaneous lupus erythematosus (CLE) after IMVT-1402 missed the primary endpoint in a Phase 2 proof-of-concept trial.

The drug, imeroprubart, is a next-generation anti-FcRn antibody. FcRn is the receptor that recycles IgG antibodies back into the blood; blocking it lowers circulating autoantibodies, the same approach behind argenx’s approved Vyvgart in myasthenia gravis. In a 57-patient, randomized, double-blind, placebo-controlled global study (NCT06980805), patients received IMVT-1402 or placebo for a 12-week treatment period. The primary endpoint was the percent change from baseline in CLASI-A, a score that measures lupus skin disease activity, at Week 12. It did not reach statistical significance, and Immunovant did not disclose the p-value or the size of the miss.

Immunovant shares (Nasdaq: IMVT) closed at $33.30 on September 25, down roughly 11% from the $37.29 close before the September 23 announcement, on volume running about 20 times the daily average. The market cap sits near $6.9 billion, a small fraction of the roughly $60 billion argenx commands for Vyvgart, the approved FcRn antibody in myasthenia gravis. Immunovant is a majority-owned subsidiary of Roivant (Nasdaq: ROIV).

The failure is program-ending but contained. The company flagged one silver lining: patients who achieved deeper IgG reductions from baseline were more likely to improve. That dose-response signal suggests the FcRn mechanism does lower the relevant antibodies, just not enough to beat placebo on the skin-activity scale in CLE.

The distinction matters because FcRn blockers look better suited to systemic lupus than cutaneous disease. Cutaneous lupus is the skin-limited form of the illness, distinct from the systemic form that attacks internal organs. Johnson & Johnson’s nipocalimab won a Phase 2 trial in SLE in January, the first FcRn drug to show efficacy in lupus, while Biogen’s litifilimab, a BDCA2 antibody, has already produced a Phase 2 win in CLE. For Immunovant, this is the second FcRn setback in under a year: its first-generation antibody batoclimab failed Phase 3 in thyroid eye disease in April. (See the broader FcRn class story.)

Safety was never the issue; IMVT-1402 showed a favorable tolerability profile consistent with prior studies.

The antibody itself is not dead. Immunovant continues Phase 3 development in Graves’ disease, myasthenia gravis, difficult-to-treat rheumatoid arthritis, chronic inflammatory demyelinating polyneuropathy, and Sjogren’s disease. Those indications, not CLE, underpin the valuation, and the exit reads as a capital-allocation call more than a verdict on the drug, according to Immunovant’s press release.

What to watch next: the Phase 3 readouts in Graves’ disease and myasthenia gravis. If those hit, this setback gets filed under wrong indication, right mechanism. If they miss too, the FcRn thesis at Immunovant looks broken.

What It Means for the Trade

The market’s verdict was swift — down roughly 11% on 20x average volume — but the reaction overstates what was actually lost. CLE was never the pillar of the $6.9 billion valuation; the Phase 3 programs in Graves’ disease and myasthenia gravis are, and those trials are still running. The exit frees balance-sheet weight and clinical-operations bandwidth to protect the shots that matter. The real information in the readout is the deeper-IgG signal: patients who achieved bigger IgG reductions from baseline were more likely to improve, which is consistent with the mechanism working and exposure being the variable. If that translates into dose selection in the remaining indications, this miss becomes cheap tuition rather than a thesis break.

The benchmark for what an FcRn platform can be worth sits in plain sight: argenx commands roughly $60 billion for one approved antibody. Immunovant trades at a small fraction of that, which is the market pricing genuine execution risk after two program-level setbacks in under a year. That gap only closes with Phase 3 wins in Graves’ or gMG — nothing before then.

Mechanism and Market Context

FcRn blockade lowers all circulating IgG, including the autoantibodies driving disease — but cutaneous lupus is a hard test for an IgG-lowering drug. Skin disease in lupus is substantially interferon-driven, inflammation that FcRn blockade only indirectly touches, and CLASI-A scores move with sun exposure and rater judgment in ways that inject variance into a 57-patient, 12-week trial. That is likely why the class’s cleaner wins — nipocalimab in systemic lupus, Vyvgart in myasthenia gravis — have come where autoantibodies drive pathology more directly. The safety profile was clean throughout, and the Phase 3 slate in Graves’, gMG, difficult-to-treat rheumatoid arthritis, CIDP and Sjogren’s remains the valuation case.

Risks and What Could Go Wrong

1. A miss in Graves’ or gMG would be the third FcRn setback in barely a year, and the market will stop paying option value for a platform with that track record.
2. The deeper-IgG-response signal is a post-hoc subgroup observation, not a validated biomarker — using it for dose selection assumes causality the trial did not prove.
3. Competition does not wait: argenx keeps widening Vyvgart’s footprint, and J&J’s nipocalimab holds a lupus win Immunovant now has no answer for.